EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review

Fizza Zulfiqar, Moazzam Shahzad, Muhammad Kashif Amin, Abhinav Vyas, Zouina Sarfraz, Anika Zainab, Hana Qasim, Dania Kaur, Naghmeh Khavandgar, Forat Lutfi, Peiman Hematti, Joseph P McGuirk und 1 weitere

Transplant Immunology · 2024-12 · 87 · 102137

DOI: 10.1016/j.trim.2024.102137 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Transplant Immunology, 2024-12. Verfasst von Fizza Zulfiqar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan …. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Rheumatic Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chimeric antigen receptor T cell (CAR-T) therapy is an emerging form of immunotherapy that has recently gained recognition for treating hematological malignancies. This successful utilization of CAR-T therapy has attracted interest in its application in refractory rheumatological diseases. Here, we will review the use of CAR-T therapy in rheumatological diseases. METHODS: Per PRISMA guidelines, a comprehensive literature search was performed on PubMed, Cochrane, and ClinicalTrials.gov using keywords for 'CAR-T cell therapy' and 'Rheumatological diseases' from inception to December 9, 2023. After screening 2977 articles, six studies reporting outcomes of CAR-T cell therapies in patients with underlying autoimmune /rheumatological diseases. Descriptive analysis was performed to represent demographics and clinical outcomes. RESULTS: A total of 101 adult patients from six studies were included in this systematic review. The median age of the participants was 50.8 years (IQR: 14.875), with ages ranging from 18 to 83 years. The included studies comprised 2 case reports, 1 case series, one observational study, and two clinical trials. The studies were conducted globally, including USA, Germany, and China. The underlying rheumatologic conditions were systemic lupus erythematosus (17.8 %), rheumatoid arthritis (23.8 %), myasthenia gravis (13.8 %), neuromyelitis optica (11.9 %), and others (32.7 %). The target of CAR-T therapy included CD-19 in four studies and B cell maturation antigen (BCMA) in two studies. All the patients were on prior therapy, including glucocorticoids and disease-modifying antirheumatic drugs. Follow-up ranged from a month to 1.5 years. Most of the studies reported improvement in the symptoms and decline in serological biomarkers of the underlying disease. The notable outcomes in the included studies were a 100 % response rate in five out of six studies. Grade 1 and 2 cytokine release syndrome (CRS) was observed in five studies. Only one study reported Grade 3 or higher CRS. 2 patients (1.98 %) developed neurotoxicity among the adverse effects. CONCLUSION: CAR-T cell therapy is a paradigm shift in managing rheumatologic diseases, with symptomatic improvement and biochemical control of these diseases. Although preliminary evidence indicates promising results, long-term follow-up and prospective clinical trials are needed to establish optimal timing and assess the safety and efficacy of CAR-T immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenRheumatic DiseasesHumansTreatment OutcomeAdultMiddle AgedAdolescentAgedT-LymphocytesYoung Adult

Stichwörter der Autor:innen

Chimeric antigen receptor T-cell therapyOutcomesRheumatological disordersSystemic review

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kan…
  • Division of Hematology and Oncology, Moffitt Cancer Center, University of South Florida, Tampa, Florida, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansa…
  • Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Florida, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States.

Zitieren

APA

Zulfiqar, F., Shahzad, M., Amin, M. K., Vyas, A., Sarfraz, Z., Zainab, A., Qasim, H., Kaur, D., Khavandgar, N., Lutfi, F., Hematti, P., McGuirk, J. P., & Mushtaq, M. U. (2024). Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review. Transplant Immunology, 87, 102137. https://doi.org/10.1016/j.trim.2024.102137

Vancouver

Zulfiqar F, Shahzad M, Amin MK, Vyas A, Sarfraz Z, Zainab A, et al. Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review. Transplant Immunology. 2024;87:102137. doi:10.1016/j.trim.2024.102137

BibTeX
@article{Zulfiqar2024,
  author = {Zulfiqar, Fizza and Shahzad, Moazzam and Amin, Muhammad Kashif and Vyas, Abhinav and Sarfraz, Zouina and Zainab, Anika and Qasim, Hana and Kaur, Dania and Khavandgar, Naghmeh and Lutfi, Forat and Hematti, Peiman and McGuirk, Joseph P and Mushtaq, Muhammad Umair},
  title = {Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review},
  journal = {Transplant Immunology},
  year = {2024},
  volume = {87},
  pages = {102137},
  doi = {10.1016/j.trim.2024.102137}
}
Kostenlos starten →